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a  b  s  t  r  a  c  t
Exposure  to elevated  levels  of  maternal  cytokines  can  lead  to functional  abnormalities  of  the  dopamin-
ergic  system  in  the  adult  offspring,  including  enhanced  amphetamine  (AMPH)-induced  locomotion.
Therefore,  it seems  reasonable  to  consider  that  offspring  of  challenged  mothers  would  behave  differ-
ently  in  models  of  addictive  behavior,  such  as  behavioral  sensitization.  Thus,  we sought  to  evaluate  the
effects  of  prenatal  exposure  to lipopolysaccharide  (LPS)  on the  locomotor  response  to  acute  and  chronic
AMPH treatment  in  male  mice  offspring.  For  this  purpose,  LPS  (Escherichia  coli  0127:B8;  120 g/kg)
was  administered  intraperitoneally  to  pregnant  Swiss  mice  on gestational  day  17. At adulthood,  male
offspring  were  studied  under  one  of  the  following  conditions:  (1)  locomotor  response  to acute  AMPH
treatment  (2.5  or 5.0  mg/kg)  in  an open  ﬁeld  test; (2) behavioral  sensitization  paradigm,  which  consists
of  a  daily  injection  of  AMPH  (1.0 mg/kg)  for  10  days  and  observation  of  locomotion  in  the open  ﬁeld  on
days  1,  5, 10  (development  phase),  15  and  17  (expression  phase).  The  LPS  stimulated  offspring  showed
enhancement  of  the locomotor-stimulant  effect  after  an  acute  AMPH  challenge  in comparison  to  baseline
and saline  pre-treated  mice.  They  also  showed  development  of  behavioral  sensitization  earlier  than  the
saline  pre-treated  group,  although  no changes  between  saline  and LPS  pre-treated  groups  were  observed
on development  or expression  of locomotor  behavioral  sensitization  to  AMPH.  Furthermore,  there  was
up-regulation  of  D1  receptor  protein  level  within  striatum  in the  LPS-stimulated  offspring  which  was
strongly  correlated  with  increased  grooming  behavior.  Taken  together,  our results  indicate  that  motor  and
dopaminergic  alterations  caused  by  maternal  immune  activation  are  restricted  to the  acute  AMPH  chal-
lenge, mostly  due  to  up-regulation  of  the  D1  receptor  within  the  mesolimbic  and  nigrostriatal  pathways,
but  no  locomotor  differences  were  observed  for  behavioral  sensitization  to  AMPH.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
The occurrence of maternal infection during pregnancy is con-
sidered an environmental risk factor that can lead to emergence
of many neuropsychiatric disorders in later life, including autism
[1] and schizophrenia [2]. It is worth noting that many studies
have attempted to mimic  the long-term consequences of mater-
nal immune activation (MIA) during pregnancy on the subsequent
brain development of the offspring. These models include exposure
to lipopolysaccharide (LPS) and polyriboinosinic-polyribocytidylic
acid (PolyI:C), which mimic  gram-negative bacterial infection and
viral infection, respectively [for recent reviews, see 3, 4].  LPS is
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recognized by toll-like receptor (TLR) 2 and TLR4, whereas PolyI:C
is recognized primarily by TLR3 [5,6]. Upon binding to TLRs, LPS
and PolyI:C both stimulate the production and release of many
pro-inﬂammatory cytokines by immune cells, including interleukin
(IL)-1, IL-6, and tumor necrosis factor (TNF)- [7,8]. Additionally,
PolyI:C is a potent inducer of type I interferon (IFN)- and IFN-
[5,9]. It is now widely accepted that elevated levels of maternal
pro-inﬂammatory cytokines during speciﬁc stages of fetal brain
development could lead to abnormalities in the adult offspring’s
central neurotransmission and behavior.
In this sense, maternal immune activation during pregnancy can
lead to functional abnormalities in the adult offspring’s dopamin-
ergic system, including altered expression of tyrosine hydroxylase
(TH) in the dorsal and ventral striatum [10,11] and the dopamine
(DA) receptors in the prefrontal cortex [11,12]. Disruption of
normal dopaminergic development may  thus represent a mech-
anism by which maternal immune challenge during pregnancy
can lead to brain and behavioral pathological changes in the off-
spring. Additionally, behavioral alterations in the offspring exposed
0166-4328/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
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to inﬂammatory stimuli include impaired social behavior [13],
reduced motor activity after an immune challenge [14], impaired
sensorimotor gating [12], and enhanced amphetamine (AMPH)-
induced locomotor response [7,11,12,15].
The locomotor response to acute AMPH treatment is routinely
used as a behavioral indicator of mesolimbic DA pathway activity
[16,17]. Moreover, enhanced susceptibility to dopaminergic stim-
ulation by acute AMPH treatment has been associated with the
positive symptoms of schizophrenia [18–20].  Therefore, in light of
the fact that sensitization of the DA pathways has been related to
schizophrenia symptoms [21], it seems reasonable to consider that
offspring exposed to pro-inﬂammatory stimuli during pregnancy
would behave differently in models of addictive behavior, such as
behavioral sensitization.
Behavioral sensitization consists of the ability of addictive drugs
to increase drug-elicited behavioral responses (locomotion) pro-
gressively after repeated exposure in laboratory animals [22]. This
has been demonstrated for different drugs of abuse, such as cocaine
[23], AMPH [24], ethanol [25], morphine [26] and nicotine [27].
Sensitization to drug-induced hyperlocomotion is a powerful tool
for the study of drug reinforcement properties and drug-seeking
behavior, which promote understanding of the mechanisms of plas-
ticity in the dopaminergic mesolimbic pathway, which is crucial to
the establishment of drug addiction and cravings [28–30].
Based on this background, we sought to determine the dif-
ferential outcomes of maternal immune activation induced by
LPS injection on locomotor response to acute and chronic AMPH
treatment (i.e., behavioral sensitization) in male mice offspring.
Furthermore, the participation of the D1 dopaminergic receptor
was also evaluated.
2. Methods
2.1. Animals
Pregnant Swiss mice from our own colony, weighing 45–60 g each, were used
(gestational day (GD) 0: presence of vaginal plug). Dams were individually housed
in standard polypropylene cages at a room with controlled temperature (22 ± 2 ◦C),
humidity (65–70%), and artiﬁcial lighting (12 h light/12 h dark cycle, lights on at
6:00 am), and the mice were given free access to Nuvilab® rodent chow (Nuvital
company, São Paulo, Brazil) and ﬁltered water. Sterilized and residue-free wood
shavings were used as animal bedding. The animals used in this study were main-
tained in accordance with the guidelines of the Committee on Care and Use of
Laboratory Animal Resources of the School of Veterinary Medicine, University of
São Paulo, Brazil (protocol # 1683/2009, FMVZ-USP).
2.2. Drugs
LPS derived from Escherichia coli serotype 0127:B8 (Sigma, USA) was freshly
dissolved in 0.9% sterile saline and was administered intraperitoneally (i.p.) to preg-
nant  mice at a dose of 120 g/kg (approximately 4 g/animal) on GD 17. This dose
and gestational period was  chosen based on previous studies in which maternal
inﬂammation was achieved without inducing preterm delivery or inﬂuencing the
offspring’s growth and sensory-motor reﬂex development [31–33].
Amphetamine sulfate (Sigma, USA) was freshly dissolved in 0.9% sterile saline
and was administered i.p. at doses of 1.0, 2.5 or 5.0 mg/kg. The doses used and time-
lag were chosen according to previous studies in which differences between prenatal
treatments were reported following higher AMPH doses [12,15], whereas behavioral
sensitization is achieved after repeated exposure to lower AMPH doses [34].
2.3. Open ﬁeld test
The open ﬁeld device consisted of a round wooden arena (40 cm in diameter,
25.5 cm high walls) painted black with an acrylic washable covering. For the obser-
vations, each mouse was  individually placed in the center of the apparatus, and the
total locomotor activity (distance traveled in centimeters) and mean velocity were
automatically measured over a period of 10 min. A video camera mounted 100 cm
above the arena was  used to collect the data, which were analyzed with the Etho-
vision 2.3 software (Noldus Information Technology, Leesburg, VA) installed on an
IBM-compatible computer placed in an adjacent room. The time spent in grooming
behavior was manually scored by an experimenter unaware of the pharmacological
treatments. The device was  washed with a 5% alcohol/water solution before place-
ment of the animals to eliminate possible biasing effects from odor clues left by the
previous subject. Control and experimental mice were intermixed for observations
that  were performed from 08:00 am to 12:00 pm.
2.4. Determination of D1R protein expression
The frontal cortex and striatum from mice were lysed in 1.5-ml Eppendorf tubes
by  sonication in the presence of an ice-cold buffer containing 120 mM Tris–HCl
(pH 6.8), 10% sodium dodecyl sulfate (SDS), 20% glycerol, 1 mM dithio-dl-threitol
(DTT), 1 mM phenylmethylsulfonyl ﬂuoride (PMSF), and a protease inhibitor cock-
tail (Sigma). Extracts were centrifuged at 13,000 × g for 13 min at 4 ◦C, and the
supernatants were collected and stored at −80 ◦C. Proteins were quantiﬁed by
the  Bradford method (Bio-Rad protein essay), and 50 g of total protein was elec-
trophoresed on a 13% SDS-polyacrylamide gel (Bio-Rad system). The proteins were
transferred to a nitrocellulose membrane (Invitrogen) using an iBlot gel transfer
system (Invitrogen). The membrane was blocked for 1 h in 5% nonfat dry milk and
1%  Tween-20 in Tris–buffered saline (pH 8.0). Subsequently, each membrane was
probed overnight at 4 ◦C with monoclonal antibodies against D1R (1:500; Chemicon,
USA) or -actin (1:1000; Sigma), followed by several washes in TBS-T. The mem-
branes were then incubated with an anti-mouse secondary antibody conjugated to
horseradish peroxidase (1:1000) for 120 min and visualized by chemiluminescence
(ECL; Amersham, USA). The bands were quantiﬁed using the software ImageJ.
2.5. Experimental procedure
2.5.1. Experiment 1: locomotor response to acute AMPH challenge
During adulthood (postnatal day 70–90), saline or LPS-treated mice offspring
(n  = 9/group) were subjected to an injection of saline prior to an open ﬁeld test to
deﬁne the baseline locomotion. Immediately after that test, all mice received a single
administration of AMPH (2.5 or 5.0 mg/kg) and were subjected to open ﬁeld test
25  min  later (AMPH induced locomotion). To prevent possible cumulative effects of
the  drug and habituation of the open ﬁeld arena, the same subject received only one
dose  of AMPH.
2.5.2. Experiment 2: behavioral sensitization to repeated AMPH treatment
2.5.2.1. Development phase. During adulthood, saline or LPS-treated mice offspring
were initially placed in the open ﬁeld for 5 min  without drug administration to
evaluate their baseline locomotor response in a novel environment (novelty test).
To  prevent the inﬂuence of reactivity to novelty in treatment outcomes, we  equated
the different treatment groups according to their baseline locomotor activity. A
t-test conﬁrmed that there were no differences in baseline activity between treat-
ment groups. Five days after the novelty test, mice of each prenatal treatment group
received vehicle (n = 7/group) or 1.0 mg/kg of AMPH (n = 13/group) for 10 days. On
days  1, 5 and 10, 10 min  after vehicle or AMPH administration, the mice were tested
for  10 min  in the open ﬁeld arena.
2.5.2.2. Expression phase. After a 5 day withdrawal period, all mice received a saline
and an AMPH (1.0 mg/kg) challenge on days 15 and 17, respectively. Ten min after
administration, locomotor activity was recorded for 10 min. Immediately after the
AMPH challenge test (day 17), the animals were decapitated in an adjacent room,
and their brains were collected. The cortex and striatum were dissected and stored
at  −80 ◦C until analysis of D1 receptor expression.
2.6. Statistical analysis
Values are expressed as the mean ± SEM. For analysis of the acute locomotor
response and the locomotion during the expression phase, a two-way analysis of
variance (ANOVA) was  performed, followed by a Bonferroni post hoc test. For the
locomotion during the development phase, a repeated measures ANOVA followed
by  a Bonferroni test was performed. For protein levels, a one-way ANOVA followed
by  Dunnett’s test was performed. Pearson’s correlation coefﬁcient was  calculated to
compare D1R protein levels in the striatum with time spent in grooming behavior
during the AMPH challenge. The results were analyzed with the GraphPad Prism 5.0
software, and the level of statistical signiﬁcance was  set at p ≤ 0.05.
3. Results
3.1. Experiment 1: locomotor response to acute AMPH challenge
3.1.1. Total locomotion
A two-way ANOVA revealed an effect of prenatal treat-
ment [F(1,11) = 8.3; p = 0.01] and AMPH challenge [F(2,22) = 96.455;
p = 0.001] on the distance traveled in centimeters. Bonferroni post
hoc analyses indicated that the 2.5 mg/kg dose of AMPH increased
locomotion in the offspring of LPS-treated dams compared to the
baseline locomotion (p ≤ 0.01) and the saline group (p ≤ 0.01). After
a 5.0 mg/kg dose, AMPH increased locomotion in the saline group
in comparison with baseline (p ≤ 0.01) and AMPH-treated mice
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Fig. 1. Locomotor response after acute administration of amphetamine (AMPH 2.5
or  5.0 mg/kg) in the offspring of mice treated with saline or LPS on GD 17. Mean
values (±SEM) of the total distance traveled (Panel A) and mean velocity (Panel B).
aDifferent from baseline of the Sal group, bdifferent from baseline of the LPS group,
cdifferent from the Sal group treated with AMPH 2.5, ddifferent from the LPS group
treated with AMPH 2.5, edifferent from the Sal group treated with AMPH 5.0.
(2.5 mg/kg, p ≤ 0.01). In addition, the LPS pre-treated group pre-
sented an increase of the stimulant effect induced by the 5.0 mg/kg
dose compared to the baseline (p ≤ 0.01) and the 2.5 mg/kg AMPH
(p ≤ 0.05) and the saline pre-treated groups (p ≤ 0.05), as shown in
Fig. 1A.
3.1.2. Mean velocity
An ANOVA test showed that changes in the mean velocity
were observed for both prenatal treatment [F(1,11) = 6.8; p = 0.05]
and AMPH challenge [F(2,22) = 89.2; p = 0.001]. The post hoc test
indicated that the 2.5 mg/kg dose of AMPH increased the mean
velocity of the offspring of LPS-treated dams compared to the base-
line locomotion (p ≤ 0.01) and the saline group (p ≤ 0.01). After a
5.0 mg/kg dose, AMPH increased velocity in the saline group in
comparison with the baseline (p ≤ 0.01) and AMPH-treated mice
(2.5 mg/kg, p ≤ 0.01). In addition, the LPS pre-treated group pre-
sented an increase in the stimulant effect induced by the 5.0 mg/kg
dose compared to the baseline (p ≤ 0.01) and the 2.5 mg/kg AMPH
(p ≤ 0.05) and the saline pre-treated groups (p ≤ 0.05), as shown in
Fig. 1B.
3.2. Experiment 2: behavioral sensitization to chronic AMPH
treatment
3.2.1. Development phase
A repeated measures ANOVA revealed an effect of the groups
[F(3,27) = 6.1; p = 0.01] and a group × time interaction [F(6,54) = 2.7;
p = 0.02] on the total locomotion during the development phase of
behavioral sensitization, as illustrated in Fig. 2. The post hoc test
indicated that the Sal-AMPH group presented an increase in loco-
motion on day 10 compared to day 1 (p ≤ 0.05) and to the Sal-Sal
group (p ≤ 0.05). On the other hand, the groups pre-treated with LPS
showed increased locomotion in response to daily AMPH adminis-
tration earlier, on day 5, in relation to the LPS-Sal group (day 5,
Fig. 2. Development phase of behavioral sensitization shows a progressive increase
in locomotor response after repeated administration of amphetamine (AMPH
1.0 mg/kg) in the offspring of mice treated with saline or LPS on GD 17. Mean values
(±SEM) of the total distance traveled during tests on day 1, 5 and 10. *LPS-AMPH vs.
LPS-Sal on day 5, **different from days 1 and 5 and from the vehicle group on day
10.
p ≤ 0.05). On day 10, the LPS-AMPH group presented a locomo-
tion pattern signiﬁcantly different from that observed on day 1
(p ≤ 0.01) and in the LPS-Sal group (p ≤ 0.05).
3.2.2. Expression phase
The total locomotion analysis in the open-ﬁeld after the saline
challenge presented a signiﬁcant treatment effect [F(1,29) = 12.8;
p = 0.001], as indicated by a two-way ANOVA (Fig. 3A). For both
prenatal treatments, mice that received daily AMPH injections
showed increased locomotion after the withdrawal period com-
pared to the respective saline group (p ≤ 0.05). The total time in
grooming behavior after the saline challenge presented a signiﬁcant
pre-treatment [F(1,27) = 4.99; p = 0.03] and treatment [F(1,27) = 6.30;
p = 0.01] effects, as indicated by a two-way ANOVA (Fig. 3C). The
grooming was  marked increased in the LPS-saline group (p < 0.01)
based on Bonferroni post hoc test.
Regarding the locomotor response to AMPH challenge, a two-
way ANOVA revealed a signiﬁcant treatment effect [F(1,29) = 13.8;
p = 0.001]. As indicated by a post hoc test, locomotion of the AMPH-
sensitized mice was  signiﬁcantly enhanced by the AMPH challenge
for both prenatal treatments (saline, p ≤ 0.05; and LPS, p ≤ 0.01;
Fig. 3B). The total time in grooming behavior after the AMPH chal-
lenge presented a signiﬁcant pre-treatment [F(1,22) = 6.58; p = 0.01]
and interaction [F(1,27) = 5.84; p = 0.02] effects, as indicated by a two-
way ANOVA (Fig. 3D). The grooming was marked increased in the
LPS-saline group (p < 0.05) based on Bonferroni post hoc test.
3.2.3. D1 receptor protein level
All of the protein expression analyses were performed by nor-
malizing the densitometric values for each experiment to those
obtained from the Sal-Sal group (control) from each brain region,
which were deﬁned as an optical density of 100%. The other mea-
surements were expressed as percentages of the Sal-Sal group, with
positive percentages indicating D1R up-regulation and negative
percentages indicating down-regulation.
No statistical differences were found in the optical density of
bands from the frontal cortical tissue among the different exper-
imental groups (p > 0.05). In the striatum, however, D1R protein
level showed signiﬁcant variations among groups [F(3,8) = 5.86;
p < 0.05], as depicted in Fig. 4A. The D1 receptor protein level was
increased in the LPS-saline group (p < 0.05) based on Dunnett’s post
hoc test. Moreover, D1R protein level in the striatum correlated
strongly with the time spent in grooming behavior during AMPH
challenge (r = 0.98, p < 0.01; Fig. 4B).
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Fig. 3. Expression of behavioral sensitization to amphetamine (AMPH) after a 5 day withdrawal period in the offspring of mice treated with saline or LPS on GD 17. Mean
values  (±SEM) of the total distance traveled and the time spent in grooming behavior after saline challenge (Panels A and C) and AMPH (1.0 mg/kg) challenge (Panels B and
D)  on days 15 and 17, respectively. aDifferent from the Sal group treated chronically with saline, cdifferent from the LPS group treated chronically with saline.
Fig. 4. Expression of the D1 dopaminergic receptor in the frontal cortex and striatum
of  offspring of mothers treated with saline or LPS on GD 17. D1 protein expression in
the striatum is up-regulated in animals receiving LPS during pregnancy and saline
during the development phase, whereas no differences were found in the frontal
cortex (Panel A). The protein levels of D1R in the striatum correlate closely with
the  increase of grooming behavior on the AMPH challenge (Panel B). The values are
expressed as mean ± SEM. *Different from the Sal-Sal group.
4. Discussion
In the present study, we report that exposure to LPS during late
gestation affects the developing brain dopaminergic system in a
speciﬁc manner. On one hand, the locomotor response induced
by a stimulant dose of AMPH is enhanced in the offspring of LPS-
treated dams. On the other hand, the emergence of dopaminergic
and behavioral disturbances provoked by maternal immune acti-
vation were not observed in the behavioral sensitization paradigm,
which is a model of addictive behavior. In this sense, the current
data indicate that disturbances in the maternal cytokine balance
during speciﬁc stages of fetal development modulate the dopamin-
ergic and behavioral outcomes in the adult offspring.
Emerging literature from epidemiologic, clinical, and preclini-
cal investigations has brought attention to the association between
maternal infection and the emergence of psychiatric disorders.
For example, the occurrence of infections during pregnancy with
Inﬂuenza, Toxoplasma gondii,  Rubella and Herpes Simplex Virus
Type 2 is believed to increase the risk of schizophrenia in chil-
dren [for review, see 35]. Although the mechanisms underlying
this epidemiological relationship remain unclear, the maternal
cytokine-associated inﬂammatory response to infection is consid-
ered a crucial link, as the identity of the pathogen seems irrelevant.
Given the complexity of schizophrenia, an approach to the develop-
ment of relevant animal models relies on focusing on speciﬁc signs
or symptoms associated with schizophrenia, rather than mimick-
ing the entire syndrome. In such cases, speciﬁc observations that
have been identiﬁed in schizophrenic patients provide a focus of
study in experimental animals.
It is worth noting that many studies using animal models have
attempted to correlate the emergence of dopaminergic distur-
bances induced by maternal immune activation to symptoms of
schizophrenia, such as impaired sensorimotor gating [12,36,37],
deﬁcits in social interaction [13] and working memory [38], and
enhanced behavioral sensitivity to acute treatment with the indi-
rect DA receptor agonist AMPH and the NMDA-receptor antagonist
MK-801 [11,12].
In this sense, our results are in agreement with previ-
ously published studies demonstrating that prenatal exposure
to pro-inﬂammatory cytokines enhances the offspring’s locomo-
tor response to acute AMPH treatment, an indicator of increased
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dopaminergic neurotransmission in the mesolimbic pathway
[11,12]. In fact, it has been demonstrated that this outcome could
be prevented by early antipsychotic treatment, which is a well-
established treatment for schizophrenic patients [39].
Nevertheless, it is worth noting that the majority of studies
have focused on PolyI:C exposure on GD 9 to evaluate this speciﬁc
outcome. In this sense, the main feature of our study is that the
stimulating effect is elicited even when the immune insult is LPS
and applied on GD 17, demonstrating that the emergence of altered
DA transmission is evidently independent of the gestation window
of immune activation. In addition, early/middle pregnancy (GD 9)
and late pregnancy (GD 17) in the mouse roughly correspond to
the middle/end of the ﬁrst trimester and to the middle of the sec-
ond trimester of human pregnancy, respectively, with respect to
developmental biology and the percentage of the gestational time
in mice and humans.
The acute psychopharmacological actions of AMPH have been
relatively well characterized. In particular, the ability to produce
psychomotor activation and reward are thought to be primarily
due to their capability to increase DA neurotransmission through
the stimulation of DA release by presynaptic vesicles. The acute
administration of psychostimulants, such as AMPH, elicits a typ-
ical dose–effect curve in rodents: whereas low doses stimulate
locomotor and exploratory behavior, higher doses produce com-
pulsive and stereotyped behaviors (such as licking and gnawing),
with no increase or even a reduction in locomotion and explo-
ration. The locomotor stimulation has been classically attributed
to the psychostimulant-induced DA release in the ventral striatum,
whereas compulsive and highly stereotyped behavior is related
to DA release within the dorsal striatum [40]. Nevertheless, it
is important to stress that the enhancement of the locomotor
stimulant effect of AMPH only took place in mice treated with
the highest dose (5.0 mg/kg), as the lowest dose (2.5 mg/kg) did
not show the stimulant effect in saline-treated offspring in our
experimental conditions. This discrepancy with the results of pre-
vious studies may  be due to differences in the strain of mice
used herein, which can account for distinct resistance to DA
stimulation.
In light of the fact that maternal immune activation promotes
enhanced acute AMPH-induced DA release within the mesolimbic
pathway and consequentially increased locomotion, we questioned
whether this enhancing property would be evident in a paradigm
of repeated exposure, such as behavioral sensitization. In this
sense, low doses of psychostimulants evoke or exacerbate psy-
chotic symptoms among schizophrenic patients [41], and drugs
used to treat both idiopathic and psychostimulant-induced psy-
chosis act primarily as DA receptor antagonists [42]. In light of these
shared characteristics, investigators have suggested that sensiti-
zation to psychostimulants may  also be a useful animal model of
schizophrenia [43].
As reviewed by Vanderschuren and Kalivas [44], behavioral sen-
sitization to psychostimulants has two distinct stages according to
drug-elicited behavior and neuroadaptations within dopaminer-
gic pathways. Notably, the development phase is characterized by
a progressive and persistent increase in locomotor activity after
repeated drug administration and is correlated with an increased
ﬁring rate in the ventral tegmental area (VTA), and synaptic DA
concentration in the nucleus accumbens is then increased. As a
consequence, after a withdrawal period, increases in the expres-
sion and activity of the DA transporter and vesicular monoamine
transporter may  contribute to the enhanced release of DA dur-
ing the expression phase (drug re-exposure). In response to DA
overﬂow through the synapse, up-regulation of postsynaptic D1
receptors within the ventral striatum is also reported. In summary,
the VTA plays an important role in the development of behavioral
sensitization, while the NAcc is mainly related to its expression.
Although much of the research regarding sensitization to
psychostimulants is focused on mesolimbic dopaminergic trans-
mission, the emerging role of the mesocortical DA system,
particularly in the medial prefrontal cortex, has gained particular
attention [45]. Yet, it has been shown that a challenge with drug-
inducing sensitization yields a marked increase in the DA levels
within the dorsal and ventral striatum than in animals receiving
the drug for the ﬁrst time [46,47] or in animals exposed to the same
drug but in a different environment [48–50].
In this sense, although mice treated with a repeated low dose
of AMPH injection presented progressively increased locomotion
during the development phase, both prenatal treatments produced
similar motor stimulation in our experimental conditions, indicat-
ing that maternal treatment with LPS did not affect the offspring’s
drug-induced locomotion in the behavioral sensitization paradigm.
Nevertheless, our results indicate that LPS-treated mice elicits
behavioral sensitization earlier than the Sal group. Additionally,
the expression of behavioral sensitization after drug re-exposure
(AMPH challenge) was evident in AMPH-sensitized mice regard-
less of prenatal treatment, demonstrating that prenatal exposure
to LPS did not intensify the expression of the offspring’s behavioral
sensitization.
Despite the fact that acute motor stimulation is enhanced in the
offspring exposed to inﬂammatory stimuli, which is suggestive of
increased dopaminergic transmission within the mesolimbic path-
way, it seems intriguing that this susceptibility did not occur in
the behavioral sensitization paradigm. However, it is essential to
remember that the neuroadaptation inherent to behavioral sensi-
tization is a much more complex process and involves extensive
changes in expression of DA-related genes and proteins, such as
the DA receptors and DA transporter.
This result contrasts with previous ﬁndings in which early-life
factors are directly involved in the propensity of adult drug addic-
tion. On one hand, insults during speciﬁc developmental stages
(i.e., the perinatal period), such as stress [51], cocaine [52] and lead
[53] exposure, high fat diet [54], and local inﬂammation [55], are
known to alter the development of behavioral sensitization to psy-
chostimulants. On the other hand, the exact mechanism by which
this alteration arises is still unknown. These two main hypotheses
have been proposed to identify factors involved on dopaminergic
modulation in response to maternal immune activation, maternal
hypoferremia and fetal hypoxia [55–57].
Furthermore, our results pointed to the occurrence of contex-
tual conditioned behavior during saline challenge, regardless of
prenatal treatment. Notably, animals who received chronic AMPH
injection throughout the 10 days of the development phase exhib-
ited increased locomotion even when they received saline after
the withdrawal period, showing that the pairing drug × open ﬁeld
was sufﬁcient to increase a drug-elicited behavior even in a drug-
free condition. Because a distinct context is repetitively paired
with the drug, it is often believed that contextual sensitized effects
are modulated by Pavlovian conditioning processes [58,59].  To
that end, the set of contextual cues acquires the ability to pro-
duce conditioned drug-like effects (i.e., enhanced dopaminergic
transmission and consequently increased locomotion), which add
progressively onto the continuous pharmacological action of the
drug as a consequence of repeated administration during the devel-
opment phase. This phenomenon has been described for many
drugs that have speciﬁc patterned behavioral effects, including
AMPH, apomorphine, cocaine, methamphetamine, morphine, and
ethanol [58,60–62].
Regarding the D1 receptor, immunoblotting of the striatum
revealed an up-regulation of the D1 receptor protein levels in the
offspring exposed to LPS during pregnancy (LPS-Sal), which in turn
was down-regulated by AMPH-induced behavioral sensitization
(LPS-AMPH). Curiously, despite the absence of D1 up-regulation
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in AMPH-sensitized mice, which was an expected ﬁnding based on
previous molecular studies, our data from experiment 2 corrobo-
rate our behavioral results from experiment 1. In this sense, the
LPS-exposed offspring seems much more prone to up-regulation
of dopaminergic receptors and consequently to stimulant effects
of acute AMPH administration mostly due to up-regulation of
the D1 receptor within the mesolimbic pathway. Moreover, the
immunoblotting revealed three bands, representing the different
isoforms of D1R detected in all groups. The different isoforms
may  correspond to the different levels of post translational mod-
iﬁcations of D1 such as glycosylation, palmitoylation and/or
phosphorylation. Indeed, these post translational processes are
involving in the anchoring of the D1R at the plasma membrane
[63]. As we have shown in the western blotting, the total amount
of D1R protein are increased in the striatum of the LPS saline
group, but decreased after repeated AMPH treatment. However,
it seems that the two highest band corresponding to the partially
and fully glycosylate forms of D1R are more evident in the striatum
of LPS saline group than in the saline-treated group, meaning that
there is more D1R at the plasma membrane in the LPS-Sal group.
Notwithstanding, the necessity for an autoradiographic study to
determine the binding between DA and its receptors, as well
as immunolocalization of these receptors, is currently acknowl-
edged.
In addition, grooming behavior during the expression phase
was found dramatically increased in the LPS-exposed offspring
which were not submitted to chronic AMPH treatment, indicat-
ing a marked correlation between D1R expression and stereotyped
behavior. Curiously, both the D1R receptor expression and
grooming behavior were prevented by previous chronic AMPH
administration in the LPS-AMPH group, probably due to activa-
tion of negative feedback of dopaminergic receptors provoked by
continuous AMPH-induced DA release. In this way, a hyper sensi-
bility of the post synaptic neurons of the striatum may  enhance the
grooming response via the thalamo-cortico-thalamic pathway.
It was already shown that acute LPS administration can dra-
matically decrease DA turnover within the ﬁrst hours [64].
Nevertheless, the present study provides additional evidence that
DA function can be programmed by immune activation dur-
ing the perinatal period as well, particularly during gestation,
and has a relevant impact upon developmental neuropsychi-
atric research since its consequences lasts until adulthood
and correlates with psychotic-like behaviors, such as enhanced
susceptibility to psychostimulants and increased stereotyped
behavior.
In conclusion, our ﬁndings indicate that maternal immune acti-
vation in late gestation enhances the locomotor response to acute
AMPH challenge and increases grooming behavior in adult male
mice offspring. However, neither development nor expression of
locomotor sensitization to AMPH was affected by prenatal treat-
ment with LPS. Additionally, up-regulation of the D1 receptor in
the striatum was found in offspring of mothers exposed to LPS,
which was signiﬁcantly correlated with stereotyped behavior. Our
results indicate that maternal immune activation elicits distinct
outcomes upon development of dopaminergic pathways, as loco-
motor responses were increased in response to acute challenge but
not to chronic treatment with AMPH.
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